RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics (NASDAQ: RAPT) has reported its Q2 2025 financial results, marking a period of strategic developments and pipeline progress. The company posted a net loss of $17.6 million for Q2 2025, showing significant improvement from the $27.7 million loss in Q2 2024.
Key highlights include strengthening the leadership team with new appointments and advancing their clinical programs. Research and development expenses decreased to $12.3 million from $22.6 million year-over-year, while G&A expenses slightly increased to $7.2 million. The company maintains a strong financial position with $168.9 million in cash and marketable securities as of June 30, 2025.
RAPT remains on track to initiate a Phase 2b trial of RPT904 in food allergy and expects topline results from partner Jemincare's Phase 2 trials in CSU and asthma in H2 2025.
RAPT Therapeutics (NASDAQ: RAPT) ha comunicato i risultati finanziari del secondo trimestre 2025, segnando un periodo di sviluppi strategici e progressi nel pipeline. La società ha registrato una perdita netta di 17,6 milioni di dollari nel Q2 2025, mostrando un miglioramento significativo rispetto alla perdita di 27,7 milioni di dollari del Q2 2024.
Tra i punti salienti, il rafforzamento del team dirigenziale con nuove nomine e l’avanzamento dei programmi clinici. Le spese per ricerca e sviluppo sono diminuite a 12,3 milioni di dollari dai 22,6 milioni dell’anno precedente, mentre le spese generali e amministrative sono leggermente aumentate a 7,2 milioni. La società mantiene una solida posizione finanziaria con 168,9 milioni di dollari in contanti e titoli negoziabili al 30 giugno 2025.
RAPT rimane sulla buona strada per avviare una fase 2b dello studio RPT904 per l’allergia alimentare e prevede i risultati principali dalle sperimentazioni di fase 2 del partner Jemincare in CSU e asma nella seconda metà del 2025.
RAPT Therapeutics (NASDAQ: RAPT) ha presentado sus resultados financieros del segundo trimestre de 2025, marcando un periodo de desarrollos estratégicos y avances en su cartera de proyectos. La compañía reportó una pérdida neta de 17,6 millones de dólares en el Q2 2025, mostrando una mejora significativa respecto a la pérdida de 27,7 millones en el Q2 2024.
Entre los aspectos destacados se incluyen el fortalecimiento del equipo directivo con nuevas incorporaciones y el avance de sus programas clínicos. Los gastos en investigación y desarrollo disminuyeron a 12,3 millones de dólares desde 22,6 millones año contra año, mientras que los gastos generales y administrativos aumentaron ligeramente a 7,2 millones. La empresa mantiene una posición financiera sólida con 168,9 millones de dólares en efectivo y valores negociables al 30 de junio de 2025.
RAPT continúa en camino de iniciar un ensayo de fase 2b de RPT904 en alergias alimentarias y espera resultados preliminares de los ensayos de fase 2 de su socio Jemincare en CSU y asma en la segunda mitad de 2025.
RAPT Therapeutics (NASDAQ: RAPT)는 2025년 2분기 재무 실적을 발표하며 전략적 발전과 파이프라인 진전을 알렸습니다. 회사는 2025년 2분기에 1,760만 달러의 순손실을 기록했으며, 이는 2024년 2분기의 2,770만 달러 손실에 비해 크게 개선된 수치입니다.
주요 내용으로는 새로운 임원진 임명으로 리더십 팀을 강화하고 임상 프로그램을 진전시킨 점이 포함됩니다. 연구개발 비용은 전년 동기 대비 1,230만 달러로 감소했으며, 일반관리비는 소폭 증가하여 720만 달러를 기록했습니다. 2025년 6월 30일 기준 회사는 1억 6,890만 달러의 현금 및 시장성 유가증권을 보유하며 견고한 재무 상태를 유지하고 있습니다.
RAPT는 식품 알레르기 치료를 위한 RPT904의 2b상 시험 개시를 계획 중이며, 파트너인 Jemincare의 만성 두드러기(CSU) 및 천식에 대한 2상 시험 주요 결과를 2025년 하반기에 기대하고 있습니다.
RAPT Therapeutics (NASDAQ : RAPT) a publié ses résultats financiers du deuxième trimestre 2025, marquant une période de développements stratégiques et de progrès dans leur pipeline. La société a enregistré une perte nette de 17,6 millions de dollars pour le T2 2025, affichant une amélioration significative par rapport à la perte de 27,7 millions de dollars au T2 2024.
Les points clés incluent le renforcement de l’équipe de direction par de nouvelles nominations et l’avancement de leurs programmes cliniques. Les dépenses de recherche et développement ont diminué à 12,3 millions de dollars contre 22,6 millions d’une année sur l’autre, tandis que les frais généraux et administratifs ont légèrement augmenté à 7,2 millions. La société maintient une solide position financière avec 168,9 millions de dollars en liquidités et titres négociables au 30 juin 2025.
RAPT reste sur la bonne voie pour lancer un essai de phase 2b de RPT904 dans les allergies alimentaires et attend les résultats principaux des essais de phase 2 de son partenaire Jemincare dans l’urticaire chronique spontanée (UCS) et l’asthme au second semestre 2025.
RAPT Therapeutics (NASDAQ: RAPT) hat seine Finanzergebnisse für das zweite Quartal 2025 veröffentlicht und damit eine Phase strategischer Entwicklungen und Fortschritte in der Pipeline markiert. Das Unternehmen verzeichnete im Q2 2025 einen Nettoverlust von 17,6 Millionen US-Dollar, was eine deutliche Verbesserung gegenüber dem Verlust von 27,7 Millionen US-Dollar im Q2 2024 darstellt.
Zu den wichtigsten Highlights zählen die Verstärkung des Führungsteams durch neue Ernennungen sowie der Fortschritt bei den klinischen Programmen. Die Forschungs- und Entwicklungskosten sanken im Jahresvergleich auf 12,3 Millionen US-Dollar von 22,6 Millionen, während die allgemeinen Verwaltungsaufwendungen leicht auf 7,2 Millionen stiegen. Das Unternehmen hält zum 30. Juni 2025 eine starke Finanzposition mit 168,9 Millionen US-Dollar an liquiden Mitteln und marktfähigen Wertpapieren.
RAPT ist weiterhin auf Kurs, eine Phase-2b-Studie von RPT904 bei Nahrungsmittelallergien zu starten und erwartet Topline-Ergebnisse aus den Phase-2-Studien des Partners Jemincare zu CSU und Asthma in der zweiten Hälfte des Jahres 2025.
- Net loss improved significantly to $17.6M in Q2 2025 from $27.7M in Q2 2024
- Strong cash position of $168.9M as of June 30, 2025
- R&D expenses decreased substantially to $12.3M from $22.6M year-over-year
- Strategic partnership with Jemincare progressing with Phase 2 trials
- Company continues to operate at a loss ($17.6M in Q2 2025)
- Increased G&A expenses to $7.2M from $6.7M year-over-year
Insights
RAPT reduced losses while maintaining strong cash position; pipeline progress with key catalysts expected H2 2025.
RAPT Therapeutics posted a significant improvement in its financial metrics with Q2 2025 net loss narrowing to
The company's liquidity position remains solid with
Looking ahead, RAPT has positioned several potential value-driving catalysts for H2 2025. Most notably, the company remains on track to initiate a Phase 2b trial of RPT904 in food allergy, and through its partnership with Jemincare, expects to report topline results from Phase 2 trials of RPT904 in chronic spontaneous urticaria (CSU) and asthma. The success of these trials could significantly impact RAPT's valuation, particularly if RPT904 demonstrates strong efficacy in these immunological conditions with substantial market opportunities.
The company has also strengthened its leadership team with strategic additions, bringing in expertise specifically in food allergy drug development and adding industry veterans to its board. These personnel moves align with RAPT's focus on advancing its diverse immunology pipeline, which management views as a key competitive advantage in the immunology space.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025.
“The first half of 2025 has been productive, with several key achievements setting the stage for important catalysts anticipated in the second half of the year,” said Brian Wong, President and CEO of RAPT. “We strengthened our team with the addition of Jessica Savage, an experienced drug developer in the food allergy space, and our board of directors with the appointments of industry veterans Drs. Scott Braunstein and Ashley Dombkowski. We have been focused on execution and as we enter the second half of the year we remain on track to initiate our Phase 2b trial of RPT904 in food allergy later this year. We also remain on track with our partner, Jemincare, to report topline results from Jemincare’s Phase 2 trials of RPT904 in CSU and asthma in the second half of this year. Lastly, we continue to advance our next-generation CCR4 pipeline and we see the diversity of our pipeline as a differentiating strength.”
Financial Results for the Second Quarter and Six Months Ended June 30, 2025
Please note: All share amounts and per share amounts in this press release have been adjusted to reflect the 1-for-8 reverse split of the Company's common stock, effected on June 16, 2025.
Second Quarter Ended June 30, 2025
Net loss for the second quarter of 2025 was
Research and development expenses for the second quarter of 2025 were
General and administrative expenses for the second quarter of 2025 were
Six Months Ended June 30, 2025
Net loss for the six months ended June 30, 2025 was
Research and development expenses for the six months ended June 30, 2025 were
General and administrative expenses for each of the six months ended June 30, 2025 and 2024 were
As of June 30, 2025, the Company had cash and cash equivalents and marketable securities of
About RAPT Therapeutics, Inc.
RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimates,” “expects,” “look forward,” “plans,” “potential” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the timing of the initiation of or data from clinical trials, expectations concerning our partnership with Jemincare, the development of our pipeline and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected or unfavorable safety or efficacy data observed during clinical studies, preliminary data and trends that may not be predictive of future data or results or that may not demonstrate safety or efficacy or lead to regulatory approval, our reliance on our partners and other third parties, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, tariffs and trade tensions, fluctuations in inflation and interest rates and other economic uncertainty), changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process and the sufficiency of RAPT’s cash resources. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
| RAPT THERAPEUTICS INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 12,340 | $ | 22,640 | $ | 24,382 | $ | 47,421 | ||||||||
| General and administrative | 7,195 | 6,690 | 14,418 | 14,427 | ||||||||||||
| Total operating expenses | 19,535 | 29,330 | 38,800 | 61,848 | ||||||||||||
| Loss from operations | (19,535 | ) | (29,330 | ) | (38,800 | ) | (61,848 | ) | ||||||||
| Other income, net | 1,892 | 1,667 | 3,992 | 3,664 | ||||||||||||
| Net loss | $ | (17,643 | ) | $ | (27,663 | ) | $ | (34,808 | ) | $ | (58,184 | ) | ||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized loss on marketable securities | (19 | ) | (37 | ) | (34 | ) | (150 | ) | ||||||||
| Total comprehensive loss | $ | (17,662 | ) | $ | (27,700 | ) | $ | (34,842 | ) | $ | (58,334 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.65 | ) | $ | (5.69 | ) | $ | (1.29 | ) | $ | (12.01 | ) | ||||
| Weighted average number of shares used in computing net loss per share, basic and diluted | 26,949,752 | 4,858,345 | 26,938,008 | 4,843,527 | ||||||||||||
| RAPT THERAPEUTICS, INC. BALANCE SHEETS (In thousands) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| Assets | (Unaudited) | (1) | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 41,886 | $ | 169,735 | ||||
| Marketable securities | 127,061 | 61,320 | ||||||
| Prepaid expenses and other current assets | 3,912 | 4,181 | ||||||
| Total current assets | 172,859 | 235,236 | ||||||
| Property and equipment, net | 970 | 1,367 | ||||||
| Operating lease right-of-use assets | 2,308 | 3,333 | ||||||
| Other assets | 2,273 | 389 | ||||||
| Total assets | $ | 178,410 | $ | 240,325 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,189 | $ | 1,275 | ||||
| Accrued expenses | 6,583 | 9,597 | ||||||
| License fees payable | — | 35,000 | ||||||
| Operating lease liabilities, current | 2,205 | 2,422 | ||||||
| Other current liabilities | 66 | 57 | ||||||
| Total current liabilities | 13,043 | 48,351 | ||||||
| Operating lease liabilities, non-current | 959 | 2,070 | ||||||
| Total liabilities | 14,002 | 50,421 | ||||||
| Commitments | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 13 | 13 | ||||||
| Additional paid-in capital | 813,734 | 804,388 | ||||||
| Accumulated other comprehensive income | 16 | 50 | ||||||
| Accumulated deficit | (649,355 | ) | (614,547 | ) | ||||
| Total stockholders’ equity | 164,408 | 189,904 | ||||||
| Total liabilities and stockholders’ equity | $ | 178,410 | $ | 240,325 | ||||
| (1) | The balance sheet for December 31, 2024 has been derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. |
FAQ
What was RAPT Therapeutics' (RAPT) net loss in Q2 2025?
How much cash does RAPT Therapeutics have as of Q2 2025?
What are the upcoming catalysts for RAPT stock in 2025?
How did RAPT Therapeutics' R&D expenses change in Q2 2025?
What recent management changes occurred at RAPT Therapeutics?
